Skip to main content
U.S. flag

An official website of the United States government

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Institute for Bioscience and Biotechnology Research (IBBR)

IBBR is a joint research institute, located in Rockville, Maryland in the heart of the I-270 Technology corridor, formed by the University of Maryland, College Park, the University of Maryland, Baltimore, and the National Institute of Standards and Technology (NIST).

IBBR exists to foster integrated, cross-disciplinary team approaches to scientific discovery, translational development and education, – and to the foster and expand the bioeconomy in the state of Maryland and across the country.  IBBR works towards these goals by: 

  • Leveraging the collective research strengths of the partnering institutions in medicine, biosciences, technology, quantitative sciences and engineering.
  • Creating innovative cross-functional collaborations that break down traditional silos and lead to pioneering research and development.
  • Working with a wide range of academic, government and industry partners to move ideas from promising theory to real-world applications.

Find out more on the IBBR website.

News and Updates

Publications

Enabling adoption of 2D-NMR for the higher order structure assessment of monoclonal antibody therapeutics

Author(s)
Robert G. Brinson, John P. Marino, Frank Delaglio, Luke W. Arbogast, Ryan M. Evans, Anthony J. Kearsley, Yves Aubin, Gregory Pierens, Xinying Jia, David Keizer, Jonas Stahle, Goran Widmalm, Chad Lawrence, Patrick Reardon, John Cort, Koichi Kato, Stuart Parnham, Andreas Blomgren, Torgny Rundlof, Kang Chen, David Keire, Thea Suter-Stahel, Gerhard Wider, Donna Baldisseri, Julie Wu, Mats Wikstrom, Medhi Mobli
Of the top ten drugs on the global market in 2016, seven of them are biologics with a combined market value of over US$60 billion. Moreover, around 2,800